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Prescribing for young people with Attention Deficit Hyperactivity Disorder in UK 
primary care: analysis of data from the Clinical Practice Research Datalink 
 
Abstract 
Background 
Guidance on management of Attention Deficit Hyperactivity Disorder [ADHD] in the UK was issued 
by the National Institute for Clinical Excellence [NICE] in 2008. No UK study has examined all 
psychotropic prescribing in young people with ADHD since the introduction of the guidance; this is 
especially relevant due to the high prevalence of psychiatric comorbidity in this population. 
Aim 
To describe primary care prescribing of ADHD and other psychotropic medication for young people 
with ADHD. 
Design and setting 
Analysis of records of patients with an ADHD diagnosis in the UK Clinical Practice Research 
Datalink from 2005 to 2013. 
Methods 
Estimation of the prevalence of prescribing of ADHD and other psychotropic medication over 8 years 
follow-up for cases aged 10 to 20 years in 2005. 
Results 
Of 9,390 ADHD cases, 61.6% (95% confidence interval (CI) = 60.6% to 62.5%) had a prescription at 
some point for ADHD medication. Prescribing of other psychotropic medication was higher in girls 
than boys (36.4% versus 22.7%; p<0.001). ADHD prescribing prevalence declined steeply between 
the ages of 16 and 18 from 37.8% (95% CI 36.6 to 38.9) to 23.7% (95% CI: 22.7 to 24.6%). There 
was a parallel increase in prescribing of other psychotropics from 3.8% (95% CI: 3.4% to 4.3%) to 
6.6% (95% CI 6.0 to 7.3%).  
Conclusion 
There is scope to optimise the management of ADHD and psychiatric comorbidities in young people, 
and a need for sustainable models of ADHD care for young adults, supported by appropriate training 
and specialist services. 
Keywords 
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Introduction 
Children, young people and adults with Attention Deficit Hyperactivity Disorder (ADHD) are at 
greater risk of experiencing a broad spectrum of poorer outcomes, including higher rates of mortality, 
injuries and accidents, as well as educational and occupational underachievement (Lichtenstein et al. 
2012; Shaw et al. 2012; Dalsgaard et al. 2015; Chang et al. 2014). There are also increased rates of 
comorbidity with other psychiatric disorders including anxiety, depression and substance misuse; the 
peak age of emergence for many of these being in late adolescence and early adulthood (Biederman et 
al. 1991; Copeland et al. 2011; Jensen and Steinhausen 2015; Fayyad et al. 2017).  Such coexisting 
disorders may affect functioning and adherence to medication and furthermore may go undiagnosed 
and hence untreated (Kooij et al. 2010; Bolea-Alamanac et al. 2014). However, despite the 
significance of comorbidities in ADHD, prescribing of other psychotropic medications in young 
people with the condition has been little studied, with most studies focussing on the prescription of 
ADHD medication only and / or on younger children (Birnbaum et al. 2013; Sikirica et al 2013). 
 
Moving from adolescence to adulthood, ADHD symptoms can become less overt (for example, 
manifesting as inner restlessness and disorganisation) and even be mistaken for the signs of other 
common psychiatric comorbidities (Asherson et al. 2007).  Sibley et al.’s (2015) systematic review of 
persistence suggested that 40-50% of adolescents with ADHD still met criteria for a diagnosis in 
adulthood where recommended methods such as age-appropriate symptom thresholds were used. 
However, despite evidence for symptom persistence, internationally, studies of prescribing patterns 
such as those by Johansen et al (2015) in the US and Zetterqvist et al. (2013) in Sweden indicate that 
there are high rates of treatment discontinuation in late adolescence. Previous UK studies of primary 
care prescribing have also reported a steep fall in prescribing prevalence of ADHD medication 
coinciding with the period during which transition from child to adult services takes place (Wong et 
al. 2009; McCarthy et al. 2012), but these studies used data collected before new guidance was issued 
by the National Institute for Health and Care Excellence (NICE) in 2008. This guidance recommends 
that young people with ADHD should be reassessed at school-leaving age to determine whether they 
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need to continue treatment into adulthood, and also states that drug treatment is the first line treatment 
for adults with moderate or severe levels of impairment resulting from their ADHD. Our recent paper 
(Newlove-Delgado et al. 2017) used the UK Clinical Practice Research Datalink to examine time to 
cessation of ADHD medication from age 16, including the most recently available data from 2005 to 
the end of 2013. However, despite the developments in guidance in treating those reaching adulthood 
the median time to cessation that we reported was 1.5 years, suggesting a continuing disparity 
between expected levels of symptom persistence and continuation of medication. 
 
However, no UK study has to date examined all psychotropic prescribing in primary care (both 
ADHD and non-ADHD medication) in children and young adults with ADHD over this more recent 
time period, which represents an important gap. In the UK, General Practitioners (GPs, primary care 
doctors) are the ‘gatekeepers’ to specialist services such as child and adolescent psychiatry clinics or 
paediatric neurodevelopmental clinics.  Whilst GPs do not usually undertake diagnosis of ADHD and 
comorbidities in children and young people, they are often responsible for prescribing regular 
medication under shared care arrangements. When young people reach the age boundary for child 
services at 16 to 18, there is considerable variation nationally in the services available to them if 
ongoing treatment is needed (Hall et al. 2015), with some areas of the UK having no available Adult 
ADHD service to support GPs in prescribing and other aspects of ADHD management. Consequently, 
knowledge of the more recent patterns both of prescribing of ADHD medication and other 
psychotropic medications in primary care will allow greater understanding of current practice in 
managing ADHD and comorbidities in young people. This will contribute to recommendations for 
commissioning of services, practice and training to improve assessment and wider availability of 
appropriate management for ADHD and comorbid conditions. 
   
The primary objective of this study was, therefore, to examine the prevalence of primary care 
prescribing of drugs used to manage ADHD and of other psychotropic medication from the 1st 
January 2005 to the 31st December 2013 for people with ADHD aged 10 to 20 in 2005. 
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Methods 
Study design 
This analysis of prescribing uses data from the UK Clinical Practice Research Datalink (CPRD), a 
large clinical database run by the Medicines and Healthcare products Regulatory Agency (MHRA) 
which includes prescribing and consultation data from primary care practices across the country 
(Herrett et al. 2015). We used the CPRD to report the prescribing prevalence of ADHD and other 
psychotropic medication and the prevalence of recorded psychiatric comorbidities in people with a 
recorded ADHD diagnosis as defined below. We included cases with ADHD aged from 10 to 20 at 
any point between 1st January 2005 and 31st December 2005, and analysed the data available on these 
cases from 1st January 2005 until 31st December 2013. This allowed the study of patterns of primary 
care prescribing during the period of transition from child to adult services, which usually takes place 
between the ages of 16 and 18 years.  
 
Inclusion criteria 
To be included, firstly, cases needed to be aged 10 to 20 at some point between 1st January 2005 and 
31st December 2005. Secondly, they needed to have a record of an ADHD diagnosis coded in their 
files at some point between birth and the end of the study period on 31st December 2013. ADHD 
diagnoses were defined as any of the 22 CPRD medical codes and primary care terms (based on ICD-
10 F90 categories) that relate to an ADHD diagnosis (Newlove-Delgado et al 2017).  
 
Identification of prescriptions and comorbid psychiatric diagnoses 
To identify prescriptions of ADHD medication, the files of included cases were searched for 
prescription records coded with any of the CPRD product codes referring to British National 
Formulary (BNF) categories of ADHD medication – e.g., stimulants, dated within the study period 
(Joint National Formulary 2015). Other psychotropic medication prescriptions were identified by 
searching for records of medications included in BNF Sections 4.1, 4.2 and 4.3 (anxiolytics, 
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antidepressants, mood stabilisers and drugs used in psychoses and related disorders). Antipsychotics 
and mood stabilisers were grouped together as one category. Comorbid psychiatric diagnoses were 
identified by searching for codes relating to ICD-10 classifications for the main categories of disorder. 
 
Analysis 
Stata SE13 (Statacorp 2015) was used for all data analysis. Prescribing prevalence of ADHD 
medication was reported, firstly, as the percentage of all cases with a recorded prescription at any 
point within the study period, and, secondly, by age. For the analysis of prescribing by age, if the 
case’s registration with a CPRD practice ended before the end of a year then that was counted as an 
incomplete year and the case was not included. As CPRD does not provide the full date of birth, the 
age was designated as the age of the case at the end of the calendar year for this analysis. 
 
We also reported the prevalence of prescribing for non-ADHD psychotropic medication and the 
prevalence of psychiatric comorbidities.  We reported prescribing by category of comorbidity. We 
reported the prevalence of concurrent prescriptions of ADHD and other psychotropic prescriptions 
occurring in the same calendar year. Finally, to examine secular changes, we reported prevalence of 
prescribing of ADHD medication by year. 
 
All protocols using patient level data from the CPRD are reviewed for scientific quality and approved 
by the Independent Scientific Advisory Committee [ISAC] on behalf of the National Research Ethics 
Service Committee. This study protocol [13_213] was granted ISAC approval in January 2013. 
 
Results 
Sample characteristics 
There were 9,390 patients with ADHD who met the inclusion criteria. Of these, 7,876 (83.9%) were 
male. The median length of time for which follow-up data were available was 8.7 years (interquartile 
range 3.2 to 9.2 years). 
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Psychiatric comorbidities 
Over a quarter of cases (26.0%, 2440/9390) in the sample had another psychiatric diagnosis recorded 
at some point during follow-up. The most common categories of comorbid psychiatric disorder were 
autism spectrum disorders (ASD) (9.9%) and anxiety or depressive disorders (9.3%) (Table 1). 
Psychiatric comorbidity was more prevalent in females than males (29.4% versus 25.3%, p = 0.001). 
 
Insert Table 1 here 
 
Prescribing at any point during follow-up 
Of all patients, 61.6% (95% CI: 60.6% to 62.5%) had at least one prescription for an ADHD 
medication during the study period. This percentage was similar between males and females (61.8% 
versus 60.4%). 
 
A quarter of all cases (24.9%; 95% CI: 24.0% to 25.8%) had at least one prescription for another 
psychotropic medication at some point during the study period, with the most commonly prescribed 
category being antidepressants (Table 2). Females had a higher prevalence of being prescribed a non-
ADHD psychotropic medication (36.4% vs 22.7%, p <0.001), in particular of being prescribed 
antidepressants and anxiolytics. 
 
Insert Table 2 here 
 
Of those with a recorded comorbidity, 49.2% (95% CI: 47.1 to 51.1%) had a prescription for a non-
ADHD psychotropic medication at any point, versus 16.8% (95% CI: 16.0 to 17.7%) of those without 
recorded comorbidity. In those with a comorbid disorder, prescribing of non-ADHD psychotropic 
medication was higher among females than in males (64.4% versus 45.7%; p<0.001). 
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There were clear differences between diagnostic groups on examining non-ADHD psychotropic 
prescribing (Table 3). Antipsychotic and mood stabiliser prescribing was highest amongst those with 
a recorded tic disorder (42.4% had a prescription at some point).  Unsurprisingly, participants with a 
recorded diagnosis of anxiety or depression were more likely than other groups to be prescribed 
antidepressants. 
 
Insert Table 3 here 
 
Concurrent prescribing of ADHD and psychotropic medication 
Just under 1 in 10 cases (8.8%, 95% CI: 8.3% to 9.4%) had a prescription for both an ADHD 
medication and a non-ADHD psychotropic medication within the same calendar year. This percentage 
was higher among females (11.1% versus 8.4% in males).  
Prescribing by age 
Prescribing by age is summarised in Figure 1. Over the transition period from child to adult services 
there was evidence of rapidly falling prevalence. Amongst 16 year olds, prevalence of prescribing of 
ADHD medication was 37.8% (95% CI: 36.6 to 38.9%) falling to 23.7% (95% CI: 22.7 to 24.6%) in 
18 year olds. In contrast, for other psychotropic prescriptions, from the age of 16 onwards there was a 
clear rise so that at the age of 18, 6.6% (95% CI: 6.0 to 7.3%) had a prescription.  
Insert Figure 1 here 
As Figure 2 demonstrates, patterns of ADHD medication prescribing by age followed a similar pattern 
in each year of the study period, with the sharpest drop in prescribing consistently seen between the 
ages of 16 and 18 years. 
Insert Figure 2 here 
 
Discussion 
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Summary 
Our results clearly demonstrate a marked decline in the prevalence of ADHD prescribing over the 
period in which transition from child to adult services takes place in the UK and a parallel rise in the 
prevalence of other psychotropic prescribing. A quarter of all cases had a prescription at some point 
for non-ADHD psychotropic medication. We found that girls with ADHD were more likely to have a 
recorded diagnosis of comorbid depression or anxiety alongside ADHD and to be prescribed non-
ADHD psychotropic medication.   
 
Strengths and limitations 
The chief strength of this analysis was the use of high quality and recent data from a national database 
capturing current practice in primary care prescribing until the end of 2013, covering a period 
following the introduction of the UK NICE ADHD guidance. 
 
In the UK, primary care databases are likely to provide the fullest picture of prescribing due to 
widespread shared-care protocols for ADHD (Ford et al. 2008). However, they fail to capture the 
smaller proportion of prescribing taking place in specialist services which might include shorter term 
trials. Prescribing for those who de-registered from their practice would also no longer be captured in 
CPRD if they did not re-register with a CPRD affiliated practice. These cases might represent a 
slightly different population, for example, those moving away for education. Although estimates of 
validity of diagnoses in the CPRD are generally high, particularly for non-acute conditions, relying on 
clinician coded diagnoses of ADHD to select cases might introduce bias (Herrett et al 2010). 
 
Perhaps the most significant limitation of this study when considering the implications regarding 
under-treatment or the appropriateness of treatment is that the dataset did not contain information on 
several important factors that may influence prescribing.  Data were not available on the severity of 
ADHD and of comorbid conditions, or on the specific indication for medication.  
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Comparison with existing literature 
The decline in prescribing of ADHD medication in late adolescence that we describe coincides with 
the period of transition from child to adult services. The decline appears steeper and in excess of what 
would be expected from follow-up studies of persistence of symptoms (Faraone et al. 2006; Sibley et 
al. 2015). When examining secular trends, this pattern was still evident in the most recent years (2012 
and 2013) included in this study. In contrast, Johansen et al.’s (2015) US study of ADHD prescribing 
found a much more gradual drop in the use of medication between the ages of 12 and 23 years, which 
supports the suggestion that prescribing will be heavily influenced by external factors such as service 
availability and attitudes of prescribers and patients (Hall et al. 2015; Matheson et al. 2013). 
 
The proportion of adults with ADHD who are prescribed drugs for ADHD appears to have risen over 
time, albeit from a very low base. In 2008, NICE estimated that 1.2% of UK adults with ADHD were 
currently receiving ADHD medication, compared to our finding that 14-15% of adults over 20 had a 
prescription.  This rise has been reported in previous studies covering earlier and overlapping time 
periods in the UK, as well as worldwide by Johansen et al. (2015), Zetterqvist et al. (2013) McCarthy 
et al. (2012), and Raman et al. (2018). Therefore, this study, which uses prescribing records from 
between 2005 and 2013, may underestimate current 2018 rates of prescribing due to rapid changes in 
practice and service development.  However, very recent reports highlight concern that some UK 
Adult ADHD services may be in the process of being decommissioned, and others have expanding 
waits, both factors which could act to influence prescribing prevalence and practice (Iacobucci, 2018). 
 
The rise in the prevalence of non-ADHD psychotropic prescribing in late adolescence is not 
unexpected, given that this is the peak age for emergence of new mental health diagnoses, whilst 
ADHD symptoms decline with age (Copeland et al. 2011). It is, however, plausible that these 
prescribing trends might represent prescribing of antidepressant or other psychotropic medications at 
the expense of treating ADHD, as symptoms of ADHD in adults may be less well recognised or 
mistaken for those of other psychiatric disorders (Kooij et al. 2010; Asherson et al. 2007). 
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Comorbidity is considered to be the rule rather than the exception in children and adults with ADHD 
(Jensen and Steinhausen 2015; Fayyad et al. 2017), and yet in this study only a quarter of all cases had 
a recorded comorbid psychiatric diagnosis during the study period. Of particular note was the very 
low prevalence of recorded substance or alcohol use disorders. Estimates from comorbidity studies 
are usually based on screening clinical samples using diagnostic instruments that will actively detect 
difficulties, and in our study diagnoses were recorded in routine practice. It is not possible to 
determine whether comorbid disorders were detected but not recorded. It is feasible, however, to 
suggest that the low prevalence we report could reflect under-diagnosis of certain common comorbid 
conditions. 
 
Almost a fifth of cases with a comorbidity had a concomitant prescription of ADHD and other 
psychotropic medication, which is similar to the findings of Sikirica et al’s (2013) European study. 
The overall prevalence of antipsychotic and mood stabiliser prescribing in our sample was 10%, 
which is in line with the results of a US study by Birnbaum et al. (2013) estimating that approximately 
11% of young people with ADHD were also prescribed antipsychotics.  A quarter of those with 
recorded comorbid ASD had antipsychotic or mood stabiliser prescriptions. Similarly, worldwide 
psychopharmacology studies suggest that antipsychotics are the most commonly prescribed class of 
drug in adults and children with ASD (Hsia et al. 2014; Jobski et al. 2016; Pineiro-Dieguez et al. 
2016); with a recent US study reporting that 20% of insured children with ASD were prescribed 
antipsychotics and 9% mood stabilisers (Madden et al. 2017). 
 
Finally, our findings imply that females are more likely to be pharmacologically treated in primary 
care for psychiatric comorbidities with ADHD than males. The literature does suggest that there are 
gender differences in the identification and management of ADHD. Girls may face higher barriers to 
referral and to receiving a diagnosis (Maniadaki et al. 2006; Groenewald et al. 2009; Ohan et al. 
2009). Given that the females in our sample had been clinically recognised and referred, they may 
have represented a more severely affected group than the males. 
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Implications for research and practice 
Whilst this was a UK-based study, there are aspects which are generalizable internationally.  For 
example, the challenges of transition and the fall in prescribing in ADHD medication over this period 
are described across international health systems (Johansen et al. 2015; Broad et al. 2017).  Primary 
care physicians in many developed countries including the US also have an important role in the 
management of ADHD in this group, meaning that the messages from this research will be relevant to 
international primary care practice and research (Bolea-Alamanac et al. 2014; Patel et al. 2017). The 
findings on the decline in ADHD prescribing, the gender differences in other psychotropic prescribing 
and the recorded prevalence of comorbid disorders all suggest that there is scope to optimise the 
management of ADHD over the transition period and improve the identification and treatment of 
psychiatric comorbidities among adolescents and adults.  
 
Recent studies by Hall et al. (2015) have reported on inadequate provision of specialist services for 
this group in the UK. Furthermore, UK GPs perceive a range of barriers in managing adolescent 
mental health problems, including time and lack of training (O’Brien et al. 2016) and also report 
problems in gaining access to such specialist services for their patients (Roberts et al. 2013). Current 
UK guidance recommends that ADHD medication requires occasional review by a specialist, and 
where such services are not available this will limit the GP’s ability to prescribe (NICE, 2008). 
Ongoing efforts are therefore required to support and encourage holistic treatment where it may be 
helpful to the young adult with ADHD. Sustainable models are needed to provide age appropriate 
services to advise and liaise with primary care and support shared care protocols (Coghill 2015;Young 
et al. 2016).  There is a strong case for further training for GPs and specialists not only on ADHD but 
on psychiatric comorbidities in the context of ADHD in both genders.   
 
In terms of future research, in order to invest in improving ADHD management, the various models of 
delivering services need to be evaluated in terms of outcomes, cost-effectiveness, and acceptability.  
A better understanding of the perspectives of service users themselves might also increase 
engagement with pharmacological and non-pharmacological interventions.  Similarly, relatively little 
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is known about what might influence the specific ADHD prescribing practices of clinicians in primary 
care. Further research into their perspectives and diagnostic and treatment practices is likely to help 
identify and address barriers to improved management. 
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Table and figure captions 
Table 1: Percentage of ADHD cases that had comorbid psychiatric disorders  
Table 2: Percentage of ADHD cases that were prescribed non-ADHD psychotropic medication by 
gender and age 
Table 3: Percentage of ADHD cases that were prescribed other psychotropic medication by type of 
recorded psychiatric comorbidity  
Figure 1: Percentage of ADHD cases that were prescribed ADHD medication and other psychotropic 
medication by age. Bars indicate 95% confidence interval 
Figure 2: Percentage of ADHD cases that were prescribed ADHD medication by age and study year  
Table 1: Percentage of ADHD cases that had comorbid psychiatric disorders  
 
 
Disorder category Percentage of cases with the disorder recorded at any point 
during follow-up 
All cases 
(N=9390) 
(95% confidence 
interval) 
By gender 
Males 
(N=7876) 
Females 
(N=1154) 
Any comorbid 
psychiatric disorder 
26.0% (25.1% to 26.9%) 25.3% 
 
29.4% 
 
Autism spectrum 
disorder (ASD) 
9.9% (9.3% to 10.5%) 10.3% 
 
7.7% 
 
Anxiety or depression 
related disorder 
9.3% (8.7% to 9.9%) 8.1% 
 
15.9% 
 
Conduct/oppositional 
defiant disorder 
5.2% (4.8% to 5.7%) 5.5% 
 
3.8% 
 
Substance/alcohol 
misuse related 
disorder 
2.1% (1.8% to 2.4%) 2.0% 
 
2.6% 
 
Any tic disorder 2.1% (1.8% to 2.4%) 2.3% 
 
1.0% 
 
Any personality 
disorder 
1.9% (1.6% to 2.2%) 1.5% 4.0% 
 
Bipolar affective 
disorder or psychosis 
0.46% (0.32% to 0.59%) 0.50% 
 
0.26% 
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Table 2: Percentage of ADHD cases that were prescribed non-ADHD psychotropic medication 
by gender and age 
Medication 
category  
(British 
National 
Formulary, 
2015) 
Percentage with at least one prescription at any point during follow-up 
All cases 
(N=9390) 
(95% confidence 
interval) 
By gender 
Males 
(N=7876) 
Females 
(N=1154) 
Any non-
ADHD 
psychotropic 
medication 
24.9% (24.0% to 25.8%) 22.7% 36.4% 
Antidepressants 
 
16.0% (15.3% to 16.8%) 13.6% 28.7% 
Anxiolytics 
 
5.8% (5.3% to 6.2%) 5.1% 9.2% 
Antipsychotics 
and mood 
stabilisers 
10.7% (10.1% to 11.3%) 10.5% 11.4% 
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Table 3: Percentage of ADHD cases that were prescribed psychotropic medication by type of 
recorded psychiatric comorbidity  
Type of recorded 
psychiatric 
comorbidity 
Percentage prescribed a drug from British National Formulary 
category of medication at any point during the study period (95% 
confidence interval) 
ADHD medication Antidepressants Antipsychotics or 
mood stabilisers 
No recorded 
comorbidity 
(N=7,055) 
61.0% 
(60.0% to 62.2%) 
10.3% 
(9.6% to 11.0%) 
6.4% 
(5.9% to 7.0%) 
Any recorded 
comorbidity 
(N=2,335) 
63.1% 
(61.1% to 65.0%) 
33.4% 
(31.5% to 35.3%) 
23.6% 
(21.9% to 25.4%) 
Autism spectrum 
disorder 
(N=927) 
67.7% 
(64.7% to 70.7%) 
19.3% 
(16.9% to 22.0%) 
25.1% 
(22.4% to 28.0%) 
Conduct/oppositional 
defiant disorders 
 (N=490) 
63.7% 
(59.3% to 67.8%) 
17.6% 
(14.4% to 21.2%) 
18.2% 
(15.0% to 21.8%) 
Depression or 
anxiety related 
disorders (N = 876) 
58.8% 
(55.5% to 62.0%) 
60.8% 
(57.6% to 64.0%) 
22.2% 
(16.9% to 28.6%) 
Tic disorders 
 (N = 198) 
63.6% 
(56.7% to 70.1%) 
22.2% 
(16.9% to 28.6%) 
42.4% 
 (35.7% to 49.5%)  
 
Figure 1 
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Figure 2 
 
